CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
类器官模型用于评估肿瘤免疫治疗的突破与挑战：推动个体化治疗的前沿工具
英文原题：Breakthroughs and challenges of organoid models for assessing cancer immunotherapy: a cutting-edge tool for advancing personalised treatments.
查看英文原题
Breakthroughs and challenges of organoid models for assessing cancer immunotherapy: a cutting-edge tool for advancing personalised treatments.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
类器官模型是评估癌症免疫疗法的有力工具；与传统模型相比，它们能更准确地再现肿瘤微环境（TME）和免疫应答。本综述聚焦类器官技术的最新进展，包括免疫细胞共培养、3D生物打印和微流控系统；这些技术可改进TME建模，并有助评估免疫检查点抑制剂（ICI）、CAR-T 疗法和溶瘤病毒等免疫疗法。尽管类器官模型在个体化癌症治疗中潜力巨大，但在免疫细胞多样性、长期培养稳定性和可重复性方面仍存在挑战。未来整合人工智能（AI）、多组学和高通量平台，有望提升类器官模型的预测能力并加速免疫治疗的临床转化。
展开英文摘要原文
Organoid models are powerful tools for evaluating cancer immunotherapy that provide a more accurate representation of the tumour microenvironment (TME) and immune responses than traditional models. This review focuses on the latest advancements in organoid technologies, including immune cell co-culture, 3D bioprinting, and microfluidic systems, which enhance the modelling of TME and facilitate the assessment of immune therapies such as immune checkpoint inhibitors (ICIs), CAR-T therapies, and oncolytic viruses.
Although these models have great potential in personalised cancer treatment, challenges persist in immune cell diversity, long-term culture stability, and reproducibility. Future developments integrating artificial intelligence (AI), multi-omics, and high-throughput platforms are expected to improve the predictive power of organoid models and accelerate the clinical translation of immunotherapy.
论文信息
- 作者
- Wang Q、Yuan F、Zuo X、Li M
- 第一作者单位
- Department of Thoracic Surgery, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210009, Jiangsu, PR China.China
- 通讯作者单位
- Department of Thoracic Surgery, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210009, Jiangsu, PR China. mingli@njmu.edu.cn.China
- 文献类型
- 综述
- 期刊
- Cell death discovery2025 May 7
- 原文标识
- PubMed 40335487 · DOI 10.1038/s41420-025-02505-w
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →